CP-47,947 appears to be a transposition error for CP-47,497, the established synthetic cannabinoid also written CP 47,497. The available scientific and forensic literature consistently identifies CP-47,497, but does not establish a separate compound under the spelling CP-47,947. This page therefore describes CP-47,497 and flags the catalogue naming issue rather than treating the two names as confirmed synonyms.
Chemistry and history
CP-47,497 is a non-classical cannabinoid developed by Pfizer during research into compounds with analgesic properties. Unlike THC, it does not contain the classical dibenzopyran ring system. Its structure is based on a cyclohexanol ring connected to a substituted phenyl group. The compound became known outside pharmaceutical research after it was identified in herbal products sold as “Spice”.
The compound is also discussed alongside its C8 homologue, commonly called cannabicyclohexanol or CP-47,497-C8. The homologues differ in the length of the alkyl substituent, a change that affects cannabinoid receptor affinity and activity. EUDA lists CP-47,497 and its homologues among the cyclohexylphenol synthetic cannabinoids (EUDA synthetic cannabinoid profile).
Pharmacology
CP-47,497 acts as a cannabinoid receptor agonist, with particularly strong activity at CB1. Published binding studies report a CB1 affinity in the low-nanomolar range. The C8 homologue has also shown high affinity and strong cannabimimetic activity in experimental models. These findings explain why the compounds were useful as pharmacological probes and why their appearance in commercial smoking mixtures raised concern (Fattore and Fratta, 2011).
Research on analogues of CP-47,497 and CP-55,940 has also shown that small structural changes can shift the balance between CB1 and CB2 activity. The results depend on stereochemistry and the assay used, so a single binding value cannot directly measure effects in humans (Huffman and colleagues, 2008).
Reported effects
There is little reliable human research that isolates the effects of CP-47,497 from those of other cannabinoids found in herbal products. Its CB1 activity is consistent with cannabis-like effects, but the clinical profile of products containing synthetic cannabinoids can be less predictable than that of cannabis.
Reports about synthetic cannabinoid products include altered perception, sedation, impaired coordination, anxiety and acute confusion. These are class-level observations and should not be presented as a confirmed symptom profile for analytically verified CP-47,497 exposure.
Toxicity and research limitations
Formal human studies of CP-47,497 are scarce. The EUDA notes that detailed pharmacology and toxicology data for many synthetic cannabinoids remain limited, while the composition and concentration of substances in herbal mixtures can vary between and within batches. This makes it difficult to link a reported reaction to one specific compound (EUDA synthetic cannabinoid profile).
The first issue to resolve for this catalogue entry is the name itself. If the intended substance is not CP-47,497, a structure, CAS number or source record is needed before a separate article can be written accurately.
Related compounds
CP-47,497 is related to CP-55,940 and the CP-47,497-C8 homologue. These are non-classical cannabinoids, chemically distinct from the indole and indazole compounds such as JWH-018.

Reviews
There are no reviews yet.